Investing.com - Compass Pathways (NASDAQ: CMPS) reported second quarter EPS of $-0.62, $0.09 better than the analyst estimate of ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...

COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising stocks. TheFly reported on February 14 that LifeSci Capital was bullish on CMPS, as the firm initiated ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-1.44451 EPS, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, and thank you for standing by. My name is ...

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

Good morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the COMPASS ...

Myriam Barthes - Journey Clinical, Inc. Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would ...

The recent earnings call for Compass Pathways Plc painted a generally positive picture, underscoring significant progress in clinical trials, regulatory interactions, and launch preparations. Despite ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 ...

The average one-year price target for COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) has been revised to $19.84 / share. This is an increase of 12.63% from the prior estimate of $17.62 ...